MCC950 . Na
| Code | Size | Price |
|---|
| AG-CR1-3615-M001 | 1 mg | £40.00 |
Quantity:
| AG-CR1-3615-M005 | 5 mg | £65.00 |
Quantity:
| AG-CR1-3615-M010 | 10 mg | £105.00 |
Quantity:
| AG-CR1-3615-M050 | 50 mg | £375.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
MCC950; CP-456,773; CRID3; 1-(1,2,3,5,6,7-Hexahydro- s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]urea
Appearance:
Crystalline solid.
CAS:
256373-96-3
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Keep cool and dry.
Hazards:
H302, H315, H319, H335
InChi:
InChI=1S/C20H23N2O5S.Na/c1-20(2,24)14-10-17(27-11-14)28(25,26)22-19(23)21-18-15-7-3-5-12(15)9-13-6-4-8-16(13)18;/h9-11,24H,3-8H2,1-2H3,(H,21,23);
InChiKey:
SNIGCXULUAXYGW-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 256373-96-3. Formula: C20H23N2NaO5S. MW: 426.5. Potent, selective and orally available NLRP3 inflammasome inhibitor. Blocks the release of IL-1beta in macrophages primed with LPS and activated with ATP or nigericin, but it does not inhibit NLRP1, NLRC4, AIM2, TLR2 signaling or priming of NLRP3. Prevents oligomerization of ASC in cells stimulated with LPS and nigericin. Active in vivo, blocking the production of IL-1beta and enhancing survival in mouse models of multiple sclerosis and cryopyrin-associated periodic syndrome (CAPS). Also active in ex vivo samples from individuals with Muckle-Wells syndrome. Potential therapeutic agent for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases.
MDL:
MFCD30478884
Molecular Formula:
C20H23N2NaO5S
Molecular Weight:
426.5
Package Type:
Vial
Precautions:
P261, P280, P301, P312, P302, P352, P304, P340, P305, P351, P338
Product Description:
Potent, selective and orally available NLRP3 inflammasome inhibitor. Blocks the release of IL-1beta in macrophages primed with LPS and activated with ATP or nigericin, but it does not inhibit NLRP1, NLRC4, AIM2, TLR2 signaling or priming of NLRP3. Prevents oligomerization of ASC in cells stimulated with LPS and nigericin. Active in vivo, blocking the production of IL-1beta and enhancing survival in mouse models of multiple sclerosis and cryopyrin-associated periodic syndrome (CAPS). Also active in ex vivo samples from individuals with Muckle-Wells syndrome. Potential therapeutic agent for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases.
Purity:
>97% (HPLC)
Signal word:
Warning
SMILES:
[NaH].CC(C)(O)C1=COC(=C1)S(=O)(=O)NC(=O)NC1=C2CCCC2=CC2=C1CCC2
Solubility Chemicals:
Soluble in water (10mg/ml), DMSO (10mg/ml), dimethyl formamide or ethanol (1mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing: R.E. Laliberte, et al.; J. Biol. Chem. 278, 16567 (2003) | Novel synthesis of 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methylethyl)furan-2-sulfonyl]urea, an antiinflammatory agent: F.J. Urban, et al.; Synth. Commun. 33, 2029 (2003) | The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes: R.C. Coll, et al.; PLoS One 6, e29539 (2011) | A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases: R.C. Coll, et al.; Nat. Med. 21, 248 (2015) | Taming the inflammasome: M. Levy, et al.; Nat. Med. 21, 213 (2015) | The Nlrp3 inflammasome admits defeat: C.J. Gross & O. Gross; Trends Immunol. 36, 323 (2015) | P2X7 receptor antagonism prevents IL-1beta release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy: M.G. Khalafalla, et al.; J. Biol. Chem. 292, 16626 (2017) | Inhibition of the NOD-like receptor protein 3 inflammasome Is protective in juvenile influenza A virus infection: B.M. Coates, et al.; Front. Immunol. 8, 782 (2017) | MCC950, the selective NLRP3 inflammasome inhibitor protects mice against traumatic brain injury: S. Ismael, et al.; J. Neurotrauma 35,1294 (2017) | Inhibitory Effect and Mechanism of Arctium lappa Extract on NLRP3 Inflammasome Activation: Y.K. Kim, et al.; Evid. Compl. Altern. Med. 6346734 (2018) | MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice: A.P. Perera, et al.; Sci. Rep. 8, 8618 (2018) | alpha1-antitrypsin mitigates NLRP3-inflammasome activation in amyloid beta1?42-stimulated murine astrocytes: T. Ebrahimi, et al.; J. Neuroinfl. 15, 282 (2018) | Pyrin dephosphorylation is sufficient to trigger inflammasome activation in familial Mediterranean fever patients: F. Magnotti, et al.; EMBO Mol. Med. 11, e10547 (2019) | Toxoplasma gondii activates a Syk-CARD9-NF-kappaB signaling axis and gasdermin D-independent release of IL-1beta during infection of primary human monocytes: W.J. Pandori, et al.; PLoS Pathog. 15, e1007923 (2019) | Interleukin-1beta suppression dampens inflammatory leukocyte production and uptake in atherosclerosis: J. Hettwer, et al.; Cardiovasc. Res. cvab337, (2021)
Related Products
| Product Name | Product Code | Supplier | Colchicine | AG-CN2-0048 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parthenolide | AG-CN2-0455 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arglabin | AG-CN2-0458 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BAY 11-7082 | AG-CR1-0013 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||